- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00065793
VLDL and LDL Particle Types as Coronary Heart Disease Risk Factors
Studieoversigt
Status
Detaljeret beskrivelse
BACKGROUND:
Plasma triglyceride concentration is an independent although relatively weak risk factor for coronary heart disease (CHD). The relative weakness of plasma triglycerides to predict CHD may be due to the substantial diversity of lipoprotein particles that carry the triglycerides, some being related to atherosclerosis and CHD more than others. The investigators have shown in patients who have had a myocardial infarction that the rather weak association between triglycerides and subsequent coronary events is secondary to a stronger relationship with specific types of VLDL remnants, those in the LDL density range that contain apoCIIl.
DESIGN NARRATIVE:
The study will evaluate VLDL and LDL particle types as predictors of initial coronary events in men from the Health Professional Follow-up Study (HPFS) and women from the Nurses Health Study (NHS). A prospective nested case-control design will be used with a total of 1000 CHD cases and 1000 matched controls, with equal numbers of men and women. The investigators will specifically investigate the role of apoCIII containing VLDL and LDL particles in diabetes by over sampling so that 50% of the patients will have type 2 diabetes mellitus. Their previous work shows that LDL apoCIII particles are independent predictors of recurrent CHD in diabetic patients who survived a myocardial infarction. They hypothesize that apoCIII may have a special role in dyslipidemia and CHD in diabetes. Secondary Aims: Besides apoCIII, other small apolipoproteins, apo C1, CII, and All are components of VLDL and LDL and modulate the metabolism of apoB lipoproteins. It is likely that these apolipoproteins have a relationship with human atherosclerosis. They will measure these apolipoproteins in VLDL and LDL and evaluate their relationship to CHD. They will also investigate the associations between these new lipoprotein risk factors and intake of foods and nutrients, physical activity, and other risk factors, including smoking, BMI, age and gender. The results will provide new means to identify nondiabetic and diabetic persons who are at high risk of developing CHD and the environmental determinants, and could form the basis for new lipoprotein targets for lipid management by diet and medicines.
Undersøgelsestype
Tilmelding (Faktiske)
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Fremadrettet
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
apoB concentration of LDL with apoC-III
Tidsramme: 10-14 years
|
observational follow-up for coronary events
|
10-14 years
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Frank Sacks, MD, Harvard School of Public Health (HSPH)
- Ledende efterforsker: Frank Sacks, MD, Brigham and Women's Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 1232
- R01HL070159 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Myokardieinfarkt
-
Sichuan Provincial People's HospitalTilmelding efter invitationRest Gated Myocardial Perfusion Imaging ved hjertesvigtKina
-
Azienda Ospedaliero Universitaria Maggiore della...Università degli Studi del Piemonte Orientale "Amedeo Avogadro"Rekruttering
-
Peking University Third HospitalAfsluttet
-
Stanford UniversitySuspenderetMyocardial brodannelseForenede Stater
-
Izmir Bakircay UniversityAfsluttetMyokardiebro af kranspulsårenKalkun
-
Fondazione Policlinico Universitario Agostino Gemelli...Afsluttet
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiAfsluttetMyokardiebro af kranspulsårenItalien
-
Centre Hospitalier Sud FrancilienAfsluttetAkut anterior koroidal infarkt (ACI) | Paramedian Pontine Infarction (IPP)Frankrig
-
RenJi HospitalAfsluttetSomatisk symptomlidelse | MyokardiebroKina
-
Imperial College LondonGuy's and St Thomas' NHS Foundation Trust; University Hospital Southampton... og andre samarbejdspartnereRekrutteringSlag | Neurokognitiv dysfunktion | Silent Cerebral Infarction | Vaskulær hjerneskadeDet Forenede Kongerige